The synthesis and inhibitory activity of the 3-substituted-4-oxa-1-azabicyclo[3.2.0]heptan-7-ones, a novel non-peptidyl class of the papain class of cysteine protease inhibitors, is reported.
Introduction
Cysteine proteases of the papain class, such as cathepsin B, L, K and S, are current important targets in medicinal chemistry. 1 They have been implicated in diseases such as osteoporosis, cancer metastasis, rheumatoid arthritis, asthma and infectious diseases. 2 Several types of cysteine proteases inhibitors 3 have been reported, such as peptide aldehydes, 4 nitriles, 5 α-ketocarbonyl compounds, 6 halomethyl ketones, 7 acyloxymethyl ketones, 8 epoxides, 9 vinyl sulfones, 10 cyclopropenone 11 and cyclohexanone. 12 These inhibitors, in general, have a peptidyl affinity fragment and a reactive group towards the thio of the cysteine residue in cysteine proteases. However, the efficacy in vivo is not as much as expected on the basis of the reported in vitro inhibitory activity and this may be due to the peptidyl fragment negatively affecting the pharmacokinetic properties. Therefore, identifying a low molecular weight nonpeptide inhibitor of cysteine proteases is of significant importance.
Results and Discussion
In our previous communication, 13 a new cysteine proteases inhibitor of 3-acetamido-4-oxa-1- .0]heptan-7-one with papain suggested that aromatic group substituted at C3 of the 4-oxa-1-azabicyclo[3.2.0]heptan-7-one ring may enhance binding with the hydrophobic S' site of the cysteine proteases. Compounds 4, 5 and 11 were predicted to be more active than the lead compound using the LUDI program 13 .
The tricyclic anthraquinone ring in compound 7 appears to have a π−π interaction with the side chain of Trp 177 of papain. Since it was reported 14 that 8-bromoacetyl-10-methylisoalloxazin can selectively react with the active site Cys 25 of papain, the isoalloxazin derivatives 6 and 8 were designed. The triazole derivatives 13 and 14 were selected due to their structural similarity to our commercial drug Tazobactam .0]heptan-7-one 9 and 12 were prepared from 4-acetoxy-2-azitidinone as described previously. 13 Catalytic hydrogenation of 9 gave an unstable 3-aminomethyl-4-oxa-1-azabicyclo[3.2.0]heptan-7-one. Thus the coupling reaction between 10 and 3-aminomethyl-4-oxa-1-azabicyclo[3.2.0]heptan-7-one was carried out in situ via the strong acylation agent, The acid chloride, which was used in the coupling reaction. Conversion of the carboxy of 10 to the acid chloride was carried out with thionyl chloride. Simultaneously, the azide 9 was reduced to 3-aminomethyl-4-oxa-1-azabicyclo[3.2.0]heptan-7-one. Without purification, mixing crude 3-aminomethyl-4-oxa-1-azabicyclo[3.2.0]heptan-7-one and the acid chloride gave the desired product 11, which was purified by chromatography. The triazole derivatives 13, 14 were prepared by cycloaddition of azide 9 or 12 with acetylene. The inhibitory activities of these compounds against papain, cathepsin B, L, K, and S were determined according to the procedure described in the literature 16 by using Cbz-Pro-Phe-Arg-AMC as substrate for papain; Cbz-Phe-Arg-AMC for cathepsin B, L and K and Cbz-Val-ValArg-AMC for cathepsin S. The inhibitory activities of the compounds are summarised in Table  1 . All of these 3-substituted 4-oxa-1-azabicyclo[3.2.0]heptan-7-one compounds showed very selective profile. They only inhibit the papain type of cysteine proteases without inhibition of serine, metallo or aspartyl proteases. Some bicyclic or tricyclic substituents at the C3 of 4-oxa-1-azabicyclo[3.2.0]heptan-7-one can significantly increase the inhibition potency. Compound 7 is a very potent non-peptide inhibitor with IC 50 values in the low nanomolar range. Molecular modeling of this compound with papain suggested that the tricylic anthraquinone moiety can interact optimally with Trp 177 in the S1' subsite and with the hydrophobic pocket in the S2' subsite of the enzyme. The pure (3R, 5S)-isomer 14 is more potent than its enantiomeric mixture 13 which is in agreement with our previous finding that the (5S) stereochemistry at C5 of 4-oxa-1-azabicyclo[3.2.0]heptan-7-one ring is important for inhibition of cysteine proteases. In summary, we have discovered that the non-peptide small molecular 3-substituted-4-oxa-1-azabicyclo[3.2.0]heptan-7-ones are very potent, selective inhibitors of the papain type of cysteine proteases. These results demonstrate that the potency of these inhibitors can be improved significantly by changing the substituents at C3 of the 4-oxa-1-azabicyclo[3.2.0]heptan-7-one ring to optimize the interactions with the S1' and S2' binding sites of the enzyme. Further modification at C3 of 4-oxa-1-azabicyclo[3.2.0]heptan-7-one could also be used to improve the pharmacokinetic properties of these inhibitors.
